Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Zezon

Rheumatology Teaneck, NJ Medical Doctor

NPI 1871866632 CMS profile 1293006

197 Cedar Ln Ste 2, Teaneck, NJ 07666

Open in the dashboard

General payments

$6,686

440 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Zezon of Teaneck, NJ is reported in the CMS Open Payments database as having received $6,686 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,791 106
2024 General $1,371 90
2023 General $1,155 76
2022 General $786 56
2021 General $715 55
2020 General $161 12
2019 General $707 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Zezon
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Anna Zezon were reported at $1,791. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Anna Zezon Rheumatology median Middle half National median
2019 $707 $744 $153–$2,687 $163
2020 $161 $462 $98–$2,027 $114
2021 $715 $531 $101–$2,153 $132
2022 $786 $627 $125–$2,303 $149
2023 $1,155 $741 $145–$2,524 $160
2024 $1,371 $830 $166–$2,660 $164
2025 $1,791 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,387 96 payments
  2. AbbVie, Inc. $1,031 72 payments
  3. Novartis Pharmaceuticals Corporation $574 31 payments
  4. Janssen Biotech, Inc. $550 34 payments
  5. ANI Pharmaceuticals, Inc. $431 30 payments
  6. AstraZeneca Pharmaceuticals LP $358 24 payments
  7. UCB, Inc. $357 24 payments
  8. Pfizer Inc. $272 23 payments
  9. Lilly USA, LLC $172 12 payments
  10. Aurinia Pharma U.S., Inc. $152 9 payments
  11. Other $1,402 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,477 433 payments
  2. Education $169 6 payments
  3. Consulting Fee $40 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $690 49 payments
  2. Enbrel $520 34 payments
  3. Otezla $512 34 payments
  4. TREMFYA $361 20 payments
  5. PURIFIED CORTROPHIN GEL $351 21 payments
  6. EVENITY $313 22 payments
  7. Cimzia $303 21 payments
  8. COSENTYX $286 15 payments
  9. XELJANZ $272 23 payments
  10. Prolia $257 19 payments
  11. Other $3,445 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

362

Median for Rheumatology: 1,511

Drug cost

$503,524

Median for Rheumatology: $1,139,948

Branded share of claims

37.6%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 56 $441,332
Teriparatide Generic 13 $35,085
Rasuvo Methotrexate/Pf Brand 15 $20,579
Hydroxychloroquine Sulfate Generic 84 $4,219
Methotrexate Methotrexate Sodium Brand 53 $1,380
Prednisone Generic 88 $349
Methotrexate Sodium Methotrexate Sodium/Pf Brand 12 $262
Allopurinol Generic 16 $253
Meloxicam Generic 25 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$584,073

Of which drugs: $482,893

Medicare patients

166

Average age 73

Services billed

41,416

131 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 46%
Diabetes 36%
Ischemic heart disease 23%
Depression 21%
Cancer 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 37 3,420 $70,439
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 128 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $173
$173 — —
RINVOQ
  • AbbVie, Inc. $166
$166 — —
TREMFYA
  • Janssen Biotech, Inc. $103
$103 — —
Enbrel
  • Amgen Inc. $91
$91 56 —
KRYSTEXXA
  • Amgen Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record